Can-Fite BioPharma Ltd.
This article was originally published in Start Up
Executive Summary
Israeli start-up Can-Fite is developing small-molecule agonists of the adenosine A3 receptor, having come to its lead compound (in-licensed from the NIH) in the course of investigating why cancer never metastasizes to muscle tissue. The firm says mechanistic studies indicate that its lead compound could also treat inflammatory conditions like rheumatoid arthritis.